GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer
K. E. Huntington, A. D. Louie, P. Srinivasan, C. Schorl, S. Lu, D. Silverberg, D. Newhouse, Z. Wu, L. Zhou, B. Borden, F. J. Giles, M. Dooner, B. A. Carneiro, W. S. El-Deiry
This study shows that elraglusib enhances immune cell activation and synergizes with anti-PD-L1 in a murine colorectal cancer model, with clinical implications for combination immunotherapy.
bioRxiv · Feb 7, 2023Cancer Biology